Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.67 |
| ▸ | CA1 | P00915 | 18/20 | 0.67 |
| ▸ | MMP1 | P03956 | 4/20 | 0.67 |
| ▸ | MMP2 | P08253 | 4/20 | 0.67 |
| ▸ | MMP9 | P14780 | 4/20 | 0.67 |
| ▸ | MMP8 | P22894 | 4/20 | 0.67 |
| ▸ | MMP13 | P45452 | 4/20 | 0.67 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898868 | 1.00 | CA2 (0.67) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL20473121 | 1.00 | CA2 (0.67) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL20473120 | 0.97 | CA2 (0.64) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL899196 | 0.97 | CA2 (0.65) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3435260 | 0.95 | CA2 (0.62) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL20476642 | 0.95 | CA2 (0.62) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2511858 | 0.92 | CA2 (0.60) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2512376 | 0.92 | CA2 (0.60) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL2516323 | 0.92 | CA2 (0.60) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3434755 | 0.92 | CA2 (0.60) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11282709-B2 | Chemical agent for forming water repellent protective film and surface treatment method for wafers | CENTRAL GLASS COMPANY, LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20010044534-A1 | Pyrimidine derivative salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-11-22 | — | — | US | disclosed |
| US-20010031875-A1 | Optically active ionic liquid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031875-A1 | Optically active ionic liquid | IK, INF2, ICMT | CA2 218/4885CA1 1040/4885MMP1 2398/4885 |
| US-20010044534-A1 | Pyrimidine derivative salt | TYMS, RTF2, UMPS | CA2 2702/4885CA1 3747/4885MMP1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.